CXCL12 and neoplasm: As previously mentioned, CXCL12 produced by FAP+ CAFs may direct tumor immune evasion in a model of human PAAD and synergized treatment of CXCL12 receptor inhibition with α-PD-L1 (32), thereby remodeling the immunosuppressive microenvironment.